John Kalyvas

My research centers on the design, synthesis, and development of cyclic peptide-based antibiotics aimed at tackling the global challenge of antibiotic resistance. By combining solid-phase peptide synthesis with advanced purification techniques, including preparative HPLC, I produce high-purity cyclic peptides for biological evaluation. These peptides are then tested for antibacterial activity and toxicity in vitro, enabling the identification of candidates with optimal therapeutic profiles.

I am currently integrating computational tools, including machine learning, into my research to accelerate the discovery process. This involves analysing structure-activity relationships, using molecular descriptors and high-dimensional data to predict antibacterial efficacy and toxicity, and generating novel peptide candidates for experimental validation. My work also incorporates NMR-based structural studies to elucidate secondary structure and refine design strategies based on molecular interactions and conformational dynamics.

Through this interdisciplinary approach, I aim to streamline the discovery of next-generation antibiotics with enhanced activity against the highest-priority ESKAPE bacterial pathogens, minimised toxicity, and potential for clinical translation. My research is driven by the urgent need to develop innovative therapeutic solutions to combat resistant bacterial infections.